Medical Care Costs and Survival Associated With Hepatocellular Carcinoma Among the Elderly

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 5, 2012, Pages 547-554

  White, Leigh Ann ^a   Menzin, Joseph ^a   Korn, Jonathan R ^a   Friedman, Mark ^a   Lang, Kathy ^a   Ray, Saurabh ^b  

^a Boston Health Economics Inc   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Cost Analysis; Economic Burden; Liver Cancer; Medicare

Indexed keywords

AGED; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; ELDERLY CARE; FEMALE; HEALTH CARE COST; HEALTH MAINTENANCE ORGANIZATION; HOSPICE; HOSPITAL PATIENT; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; SURVIVAL TIME;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; SURVIVAL ANALYSIS;

EID: 84859868904     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.12.031     Document Type: Article

References (22)

1. McGlynn K.A., Tarone R.E., El-Serag H.B. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2006, 15:1198-1203.
2. Gomaa A.I., Khan S.A., Toledano M.B., et al. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008, 14:4300-4308.
3. But D.Y., Lai C.L., Yuen M.F. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008, 14:1652-1656.
4. McGlynn K.A., London W.T. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005, 19:3-23.
5. Llovet J.M., Fuster J., Bruix J. Prognosis of hepatocellular carcinoma. Hepatogastroenterology 2002, 49:7-11.
6. Altekruse S.F., McGlynn K.A., Reichman M.E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009, 27:1485-1491.
7. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37:429-442.
8. Yau T., Chan P., Epstein R., et al. Management of advanced hepatocellular carcinoma in the era of targeted therapy. Liver Int 2009, 29:10-17.
9. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
10. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
11. Abou-Alfa G.K., Johnson P., Knox J.J., et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010, 304:2154-2160.
12. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. National Comprehensive Cancer Network, 2010 National Comprehensive Cancer Network, Accessed November 17, 2010. http://www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf.
13. Lang K., Danchenko N., Gondek K., et al. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 2009, 50:89-99.
14. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
15. Lang K., Marciniak M.D., Faries D., et al. Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States. Value Health 2009, 12:481-488.
16. Campbell J.D., Ramsey S.D. The costs of treating breast cancer in the US: a synthesis of published evidence. Pharmacoeconomics 2009, 27:199-209.
17. Rao S., Kubisiak J., Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat 2004, 83:25-32.
18. Lang K., Lines L.M., Lee D.W., et al. Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare data. Clin Gastroenterol Hepatol 2009, 7:198-204.
19. SEER cancer statistics review 1975-2007. National Cancer Institute, 2010 National Cancer Institute, Accessed November 17, 2010. http://seer.cancer.gov/csr/1975_2007/index.html.
20. Schneeweiss S., Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005, 53:337.
21. Surveillance, epidemiology, and end results (SEER): bibliography. National Cancer Institute National Cancer Institute, Accessed February 6, 2008. http://seer.cancer.gov/cgi-bin-pubsearch/pubsearch/index.pl#results.
22. FDA approval of sorafenib tosylate. National Cancer Institute, 2007 National Cancer Institute, Accessed November 17, 2010. http://www.cancer.gov/cancertopics/druginfo/fda-sorafenib-tosylate.